An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics
- 1 May 2003
- journal article
- research article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 4 (3) , 231-239
- https://doi.org/10.1517/phgs.4.3.231.22691
Abstract
Methods of economic evaluation, especially cost-effectiveness analysis and cost-benefit analysis, are widely used to examine new healthcare technologies. However, few economic evaluations of pharmacogenomics have been conducted, and pharmacogenomic researchers may be unfamiliar with how to review or conduct these analyses. This review provides an overview of the methods of economic evaluation and examples of where they have been applied to pharmacogenomics. We discuss the steps in conducting a cost-effectiveness or cost-benefit analysis, demonstrating these steps using specific examples from the pharmacogenomics literature.Keywords
This publication has 19 references indexed in Scilit:
- Population Screening in the Age of Genomic MedicineNew England Journal of Medicine, 2003
- The Cost‐Effectiveness of Interleukin‐1 Genetic Testing for Periodontal DiseaseThe Journal of Periodontology, 2002
- Genomic Medicine — A PrimerNew England Journal of Medicine, 2002
- Getting Ready for Gene-Based MedicineNew England Journal of Medicine, 2002
- Hereditary haemochromatosis: a realistic approach to prevention of iron overload disease in the populationBest Practice & Research Clinical Haematology, 2002
- Health and Economic Benefits of Increased β-Blocker Use Following Myocardial InfarctionJAMA, 2000
- Assessing the cost-effectiveness of pharmacogenomicsAAPS PharmSci, 2000
- What Philosophy Might be About: Some Socio-philosophical SpeculationsInquiry, 2000
- Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis CHepatology, 1999
- Medical and Societal Consequences of the Human Genome ProjectNew England Journal of Medicine, 1999